At the news
? BULLISHIMPACT 6/10 8-K filed Nov 5, 2026 at 07:05 ET
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133.0M (up 9.0% YoY from $122.1M) and GAAP EPS of $0.36 (up from $0.23), beating consensus estimates of $121.6M and $0.31. The company raised full-year 2026 guidance for the second consecutive quarter: LINZESS U.S. net sales to $1.20-$1.25B, total revenue to $485-$510M, and adjusted EBITDA to >$350M. LINZESS U.S. net sales reached $324.9M in Q3, with year-to-date sales of $880M already exceeding full-year 2025.
- Q3 2026 total revenue $133.0M vs $122.1M YoY, beating consensus of $121.6M
- GAAP EPS $0.36 vs $0.23 YoY, beating consensus of $0.31
- Full-year 2026 guidance raised: LINZESS net sales to $1.20-$1.25B, total revenue to $485-$510M, adjusted EBITDA >$350M
- LINZESS U.S. net sales $324.9M in Q3, up 3.2% YoY; YTD $880M exceeds full-year 2025 total
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access